Basic Science and Dialysis: Disturbances of Acquired Immunity in Hemodialysis Patients
暂无分享,去创建一个
[1] I. Kushner. Regulation of the Acute Phase Response by Cytokines , 2015, Perspectives in biology and medicine.
[2] O. Ringdén,et al. Lymphocytes from multitransfused uremic patients have poor MLC reactivity. , 2008, Tissue antigens.
[3] E. Thorsby,et al. The effect of blood transfusions on renal transplantation. Studies of 395 patients registered for transplantation with a first cadaveric kidney. , 2008, Tissue antigens.
[4] T. Eleftheriadis,et al. No effect of serum parathyroid hormone level on antigen presenting cell-dependent T-cell reactivity in hemodialysis patients , 2007, International Urology and Nephrology.
[5] R. Vanholder,et al. Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[6] H. Koyama,et al. Body fat mass and lean mass as predictors of survival in hemodialysis patients. , 2006, Kidney international.
[7] N. Vaziri,et al. Naïve and central memory T-cell lymphopenia in end-stage renal disease. , 2006, Kidney international.
[8] B. Ritz,et al. Malnutrition and energy restriction differentially affect viral immunity. , 2006, The Journal of nutrition.
[9] T. Eleftheriadis,et al. T-Cell zeta chain expression, phosphorylation and degradation and their role in T-cell signal transduction and immune response regulation in health and disease , 2006 .
[10] A. Reiss,et al. Atherosclerosis: Immune and Inflammatory Aspects , 2006, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
[11] M. Rocco,et al. Are nutritional status indicators associated with mortality in the Hemodialysis (HEMO) Study? , 2005, Kidney international.
[12] T. Eleftheriadis,et al. The value of serum antilipoarabinomannan antibody detection in the diagnosis of latent tuberculosis in hemodialysis patients. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[13] P. Aljama,et al. Lymphocyte Apoptosis: Role of Uremia and Permeability of Dialysis Membrane , 2005, Nephron Clinical Practice.
[14] B. Rutkowski,et al. Long-term therapy with recombinant human erythropoietin increases CD8+ T-cell apoptosis in haemodialysis patients. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[15] I. Karayaylali,et al. Is there any relationship between serum levels of interleukin-10 and atherosclerosis in hemodialysis patients? , 2005, Scandinavian journal of urology and nephrology.
[16] Joan L. Robinson,et al. Efficacy of Pneumococcal Immunization in Patients with Renal Disease – What Is the Data? , 2004, American Journal of Nephrology.
[17] A. Asakawa,et al. Cancer anorexia-cachexia syndrome: cytokines and neuropeptides , 2004, Current opinion in clinical nutrition and metabolic care.
[18] W. K. Bolton,et al. Prospective study of the immune effects of normalizing the hemoglobin concentration in hemodialysis patients who receive recombinant human erythropoietin. , 2004, Journal of the American Society of Nephrology : JASN.
[19] A. Lalvani,et al. Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients. , 2004, Kidney international.
[20] Mark M Davis,et al. T cell killing does not require the formation of a stable mature immunological synapse , 2004, Nature Immunology.
[21] B. Jaber,et al. Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] B. Walse,et al. Interplay Between Superantigens and Immunoreceptors , 2004, Scandinavian journal of immunology.
[23] D. Roelen,et al. Pretransplant blood transfusions revisited: a role for CD4+ regulatory T cells?1 , 2004, Transplantation.
[24] T. Eleftheriadis,et al. Impaired T Cell Proliferation and Zeta Chain Phosphorylation after Stimulation with Staphylococcal Enterotoxin-B in Hemodialysis Patients , 2004, Nephron Clinical Practice.
[25] Arup K Chakraborty,et al. The Immunological Synapse Balances T Cell Receptor Signaling and Degradation , 2003, Science.
[26] L. Szczech,et al. White blood cells as a novel mortality predictor in haemodialysis patients. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[27] R. Poduval,et al. Tuberculosis screening in dialysis patients--is the tuberculin test effective? , 2003, Clinical nephrology.
[28] G. London,et al. Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. , 2003, Kidney international. Supplement.
[29] B. Jaber,et al. Defective Interleukin-10 Synthesis by Peripheral Blood Mononuclear Cells among Hemodialysis Patients , 2003, Blood Purification.
[30] K. Hassan,et al. The Effect of Erythropoietin Therapy and Hemoglobin Levels on the Immune Response to Engerix-B Vaccination in Chronic Kidney Disease , 2003, Renal failure.
[31] Mai-Szu Wu,et al. Extrapulmonary Tuberculosis in Chronic Hemodialysis Patients , 2003, Renal failure.
[32] F. Port,et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. , 2002, Kidney international.
[33] Peter Stenvinkel,et al. The malnutrition, inflammation, and atherosclerosis (MIA) syndrome -- the heart of the matter. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[34] G. Malik,et al. Eleven years of experience with dialysis associated tuberculosis. , 2002, Clinical nephrology.
[35] Mark M. Davis,et al. Direct observation of ligand recognition by T cells , 2002, Nature.
[36] G. Heine,et al. A shift in the Th1/Th2 ratio accompanies the clinical remission of systemic lupus erythematosus in patients with end‐stage renal disease , 2002 .
[37] H. Karakayalı,et al. Role of parathormone levels on T-cell response in hemodialysis patients. , 2002, Transplantation proceedings.
[38] T. Georg,et al. Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. , 2002, Kidney international.
[39] J. Sugimura,et al. Long-term graft survival with or without donor-specific transfusion in cyclosporine era in one haplo-identical living-related renal transplant recipients beyond the first year: a 19-year experience. , 2002, The Tohoku journal of experimental medicine.
[40] F. Sánchez‐Madrid,et al. Cell adhesion and polarity during immune interactions , 2002, Immunological reviews.
[41] B. Rutkowski,et al. Long-term therapy with recombinant human erythropoietin decreases percentage of CD152(+) lymphocytes in primary glomerulonephritis haemodialysis patients. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[42] A. Yildiz,et al. Comparative Effect of Oral Pulse and Intravenous Calcitriol Treatment in Hemodialysis Patients: The Effect on Serum IL-1 and IL-6 Levels and Bone Mineral Density , 2002, Nephron.
[43] M. Girndt,et al. The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. , 2001, Kidney international.
[44] W. Ambrosius,et al. A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[45] P. Kimmel,et al. Biocompatibility of Hemodialysis Membranes: Interrelations between Plasma Complement and Cytokine Levels , 2001, Blood Purification.
[46] A. Dal Canton,et al. Polarization of T-helper lymphocytes toward the Th2 phenotype in uremic patients. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[47] L. Agodoa,et al. Etiology of bacterial septicemia in chronic dialysis patients in the United States. , 2001, Clinical nephrology.
[48] Michael Loran Dustin. Role of Adhesion Molecules in Activation Signaling in T Lymphocytes , 2001, Journal of Clinical Immunology.
[49] P. Aljama,et al. Role of Adhesion Molecules in Mononuclear Cell Apoptosis Induced by Cuprophan Hemodialysis Membranes , 2001, Nephron.
[50] K. Nitta,et al. Analysis of lupus activity in end-stage renal disease treated by hemodialysis. , 2001, Internal medicine.
[51] R Cornet,et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[52] K. Chou,et al. Tuberculosis in Maintenance Dialysis Patients , 2001, Nephron.
[53] M. Girndt,et al. Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. , 2001, Kidney international.
[54] J. Im,et al. Tuberculosis in patients with end-stage renal disease. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[55] C. Tetta,et al. C REACTIVE PROTEIN IN PATIENTS WITH CHRONIC RENAL DISEASES , 2001, Renal failure.
[56] P. Stenvinkel. Malnutrition and Chronic Inflammation as Risk Factors for Cardiovascular Disease in Chronic Renal Failure , 2000, Blood Purification.
[57] K. Chou,et al. Tuberculin Skin Test and Anergy in Dialysis Patients of a Tuberculosis-Endemic Area , 2000, Nephron.
[58] B. Jaber,et al. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. , 2000, Kidney international.
[59] E M Walker,et al. Effects of iron overload on the immune system. , 2000, Annals of clinical and laboratory science.
[60] C. Zoccali,et al. Inflammation is associated with carotid atherosclerosis in dialysis patients , 2000, Journal of hypertension.
[61] M. Girndt,et al. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[62] T. Vachharajani,et al. Diagnosis and Treatment of Tuberculosis in Hemodialysis and Renal Transplant Patients , 2000, American Journal of Nephrology.
[63] P. Stenvinkel,et al. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[64] V. Jorgetti,et al. Immune response in hemodialysis patients: is there any difference when low and high iPTH levels are compared? , 2000, Clinical nephrology.
[65] Y. Moriyama,et al. Recombinant human erythropoietin stimulates production of interleukin 2 by whole blood cell cultures of hemodialysis patients. , 2000, Artificial organs.
[66] M. Girndt,et al. Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[67] M. Arias,et al. B lymphopenia in uremia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[68] T. Greene,et al. Relationship between nutritional status and the glomerular filtration rate: results from the MDRD study. , 2000, Kidney international.
[69] V. Jorgetti,et al. Restoration of Impaired T-Cell Proliferation after Parathyroidectomy in Hemodialysis Patients , 2000, Nephron.
[70] H. DeLuca,et al. Dietary calcium is a major factor in 1,25-dihydroxycholecalciferol suppression of experimental autoimmune encephalomyelitis in mice. , 1999, The Journal of nutrition.
[71] S. Kurashige,et al. Characteristic Cytokine Products of Th1 and Th2 Cells in Hemodialysis Patients , 1999, Nephron.
[72] J. Tokars,et al. Tuberculosis in Hemodialysis Patients in New Jersey: A Statewide Study , 1999, Infection Control & Hospital Epidemiology.
[73] I. Bruce,et al. Extrarenal disease activity in systemic lupus erythematosus is not suppressed by chronic renal insufficiency or renal replacement therapy. , 1999, The Journal of rheumatology.
[74] N. K. Krane,et al. Persistent lupus activity in end-stage renal disease. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[75] P. Stenvinkel,et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. , 1999, Kidney international.
[76] H. Breitbart,et al. Impaired lymphocyte calcium metabolism in end-stage renal disease: enhanced influx, decreased efflux, and reduced response to mitogen. , 1999, The Journal of laboratory and clinical medicine.
[77] V. Cantaluppi,et al. CD40-CD154 interaction in experimental and human disease (review). , 1999, International journal of molecular medicine.
[78] M. Girndt,et al. Influence of dialysis with polyamide vs haemophan haemodialysers on monokines and complement activation during a 4-month long-term study. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[79] S. Anker,et al. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. , 1999, Chest.
[80] F. Locatelli,et al. Antiphospholipid (aPL) antibodies in end-stage renal disease. , 1999, Journal of nephrology.
[81] C. Wanner,et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. , 1999, Kidney international.
[82] J. Fitzgerald,et al. Risk of tuberculosis in dialysis patients: a population-based study. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[83] M. Girndt,et al. Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. , 1998, Journal of the American Society of Nephrology : JASN.
[84] M. Sever,et al. Tuberculin responsiveness in hemodialysis patients. , 1998, Chest.
[85] W. Owen,et al. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. , 1998, Kidney international.
[86] D. Serur,et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[87] J. Mege,et al. IL-10 synthesis and secretion by peripheral blood mononuclear cells in haemodialysis patients. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[88] R. Strawderman,et al. Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[89] H. DeLuca,et al. 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. , 1998, Journal of immunology.
[90] V. Fraser,et al. Tuberculosis infection and anergy in hemodialysis patients. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[91] A. Abbas,et al. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. , 1998, Science.
[92] B. Lindholm,et al. Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. , 1998, Kidney international.
[93] A. Terashi,et al. T-cell activation modified by parathyroid hormone (PTH) in patients with end-stage renal disease. , 1997, Clinical nephrology.
[94] Hervé Groux,et al. A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis , 1997, Nature.
[95] K. Okasha,et al. Immunoglobulin G subclasses and susceptibility to allosensitization in humans. , 1997, Clinical nephrology.
[96] H. Kirchner,et al. Low efficiency of active immunization against diphtheria in chronic hemodialysis patients. , 1997, Kidney international.
[97] R. Peces,et al. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[98] M. Newport,et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. , 1996, The New England journal of medicine.
[99] D. Birmingham,et al. Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients. , 1996, Kidney international.
[100] J. Klippel,et al. End-stage renal disease and systemic lupus erythematosus. , 1996, The American journal of medicine.
[101] J. Bluestone,et al. CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.
[102] T. Mosmann,et al. The expanding universe of T-cell subsets: Th1, Th2 and more. , 1996, Immunology today.
[103] M. Girndt,et al. Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[104] B. Hoen,et al. Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[105] M. Girndt,et al. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. , 1995, Kidney international.
[106] D. Brennan,et al. Beneficial effects of donor-specific transfusions on long-term renal allograft function. , 1995, Transplantation proceedings.
[107] P. Jungers,et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. , 1995, Journal of immunology.
[108] C. Gasche,et al. Functional characterization of cytokine autoantibodies in chronic renal failure patients. , 1994, Kidney international.
[109] R. Vanholder,et al. Uremic toxicity: the middle molecule hypothesis revisited. , 1994, Seminars in nephrology.
[110] H. DeLuca,et al. 1α,25-dihydroxyvitamin D3 a nd 19-nor-1α,25-dihydroxyvitamin 32 suppress immunoglobulin production and thymic lymphocyte proliferation in vivo , 1993 .
[111] A. Sher,et al. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[112] C. Via,et al. B-cell and T-cell function in systemic lupus erythematosus. , 1993, Current opinion in rheumatology.
[113] B. Fleischer,et al. T cell activation defect in hemodialysis patients: evidence for a role of the B7/CD28 pathway. , 1993, Kidney international.
[114] J. Bergström,et al. Nutrition and adequacy of dialysis in hemodialysis patients. , 1993, Kidney international. Supplement.
[115] Corry Rj,et al. The effect of transfusions on renal allograft survival in the cyclosporine era: a single center report. , 1993 .
[116] H. DeLuca,et al. Vitamin D deficiency suppresses cell-mediated immunity in vivo. , 1993, Archives of biochemistry and biophysics.
[117] C. Hsieh,et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. , 1993, Science.
[118] M. Oppermann,et al. Gene expression of interleukin-1β during hemodialysis , 1993 .
[119] R. Vanholder,et al. Correction of deficient phagocytosis during erythropoietin treatment in maintenance hemodialysis patients. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[120] L. Pączek,et al. Improved Immunoglobulin Production in Dialysis Patients Treated with Recombinant Erythropoietin , 1992, The International journal of artificial organs.
[121] D. Churchill,et al. Canadian Hemodialysis Morbidity Study. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[122] C G Figdor,et al. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.
[123] O. Götze,et al. The role of C5a in interleukin-6 production induced by lipopolysaccharide or interleukin-1. , 1991, Immunology.
[124] M. Croft,et al. Helper T‐Cell Subsets: Phenotype, Function and the Role of Lymphokines in Regulating their Development , 1991, Immunological reviews.
[125] R. Kaempfer,et al. Regulation of interleukin-2 and interferon-γ gene expression in renal failure , 1991 .
[126] P. Van der Niepen,et al. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. , 1991, Kidney international.
[127] C. Baldamus,et al. Immunodeficiency in ESRD-patients is linked to altered IL-2 receptor density on T cell subsets. , 1991, Journal of clinical & laboratory immunology.
[128] R. Vanholder,et al. Phagocytosis in uremic and hemodialysis patients: a prospective and cross sectional study. , 1991, Kidney international.
[129] C. Dinarello,et al. Recombinant C5a stimulates transcription rather than translation of interleukin-1 (IL-1) and tumor necrosis factor: translational signal provided by lipopolysaccharide or IL-1 itself. , 1990, Blood.
[130] R. Riggio,et al. Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. , 1990, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[131] J. Berden,et al. Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis , 1990 .
[132] E. Ritz,et al. Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. , 1990, Kidney international.
[133] T. Tabata,et al. In vivo Effect of 1α-Hydroxyvitamin D3 on Interleukin-2 Production in Hemodialysis Patients , 1988 .
[134] E. Ritz,et al. Cuprammonium membranes stimulate interleukin 1 release and arachidonic acid metabolism in monocytes in the absence of complement. , 1988, Kidney international.
[135] P. Fondu,et al. Impaired neutrophil defense against Yersinia enterocolitica in patients with iron overload who are undergoing dialysis. , 1988, The Journal of laboratory and clinical medicine.
[136] J. Davis,et al. Seroresponse to hepatitis B vaccine in patients and staff of renal dialysis centers, Wisconsin. , 1988, American journal of epidemiology.
[137] P. Marckmann. Nutritional status of patients on hemodialysis and peritoneal dialysis. , 1988, Clinical nephrology.
[138] K. Schaefer,et al. Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. , 1987, The Quarterly journal of medicine.
[139] S. Meuer,et al. Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses. , 1987, The Journal of clinical investigation.
[140] C. Pollock,et al. Dialysis and transplantation in patients with renal failure due to systemic lupus erythematosus. The Australian and New Zealand experience. , 1987, Australian and New Zealand journal of medicine.
[141] R. Schuurman,et al. Blood transfusion suppresses cutaneous cell-mediated immunity. , 1986, Clinical and experimental immunology.
[142] D. de Zeeuw,et al. Immune response to two different hepatitis B vaccines in haemodialysis patients: a 2-year follow-up. , 1985, Nephron.
[143] J. Vanherweghem,et al. Impaired phagocytic activity of neutrophils in patients receiving haemodialysis: the critical role of iron overload. , 1985, British medical journal.
[144] J. Cameron,et al. End-stage renal failure in systemic lupus erythematosus with nephritis. , 1984, Clinical nephrology.
[145] W. Szmuness,et al. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. , 1984, The New England journal of medicine.
[146] S. Teitelbaum,et al. Parathyroid hormone receptors in circulating human mononuclear leukocytes. , 1984, The Journal of biological chemistry.
[147] J. Kopple,et al. Nutritional status and lymphocyte function in maintenance hemodialysis patients. , 1984, The American journal of clinical nutrition.
[148] K. Kamata,et al. Immunosuppressive factors in uraemic sera are composed of both dialysable and non-dialysable components. , 1983, Clinical and experimental immunology.
[149] B. Descamps-Latscha,et al. In vitro suppression of cell-mediated immunity by ferroproteins and ferric salts. , 1983, Cellular immunology.
[150] D. Klatzmann,et al. SUPPRESSION OF LYMPHOCYTE REACTIVITY BY BLOOD TRANSFUSIONS IN UREMIC PATIENTS: I. PROLIFERATIVE RESPONSES , 1983, Transplantation.
[151] N. Coplon,et al. The long-term clinical course of systemic lupus erythematosus in end-stage renal disease. , 1983, The New England journal of medicine.
[152] H. Sakagami,et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[153] E. Friedman,et al. Intact antibody response to pneumococcal capsular polysaccharides in uremia and diabetes. , 1980, JAMA.
[154] A. Polliack,et al. Suppressive Effect of Ferritin on in Vitro Lymphocyte Function , 1979, British journal of haematology.
[155] J. Soulillou,et al. BENEFICIAL EFFECT OF BLOOD TRANSFUSION: ROLE OF THE TIME INTERVAL BETWEEN THE LAST TRANSFUSION AND TRANSPLANTATION1 , 1979, Transplantation.
[156] R. Sampliner. The duration of hepatitis B surface antigenemia. , 1979, Archives of internal medicine.
[157] E. Lustbader,et al. Host responses to hepatitis B infection in patients in a chronic hemodialysis unit. , 1977, Kidney international.
[158] P. Terasaki,et al. PROLONGATION EFFECT OF BLOOD TRANSFUSIONS ON KIDNEY GRAFT SURVIVAL , 1976, Transplantation.
[159] K. Nolph,et al. Antibodies to nuclear antigens in patients undergoing long-term hemodialysis. , 1976, The American journal of medicine.
[160] G. Barsotti,et al. Toxicity arising from guanidine compounds: role of methylguanidine as a uremic toxin. , 1975, Kidney international. Supplement.
[161] M. K. Mann,et al. Hepatitis B infection. A point-prevalence study in 15 US hemodialysis centers. , 1974 .
[162] J. Sanford,et al. Defective cellular immunity in renal failure: depression of reactivity of lymphocytes to phytohemagglutinin by renal failure serum. , 1971, The Journal of clinical investigation.
[163] Hirokazu Honda,et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[164] P. Rautenberg,et al. Influenza subtype-specific IgA, IgM and IgG responses in patients on hemodialysis after influenza vaccination , 2005, Infection.
[165] P. Aljama,et al. Monocytes from dialysis patients exhibit characteristics of senescent cells: does it really mean inflammation? , 2005, Contributions to nephrology.
[166] K. Kalantar-Zadeh,et al. A low lymphocyte percentage is a predictor of mortality and hospitalization in hemodialysis patients. , 2005, Clinical nephrology.
[167] J. Potter,et al. Blood pressure in acute stroke. , 2004, Age and ageing.
[168] Fang Hc,et al. Tuberculosis in patients with end-stage renal disease. , 2004 .
[169] G. Heine,et al. A shift in the Th(1)/Th(2) ratio accompanies the clinical remission of systemic lupus erythematosus in patients with end-stage renal disease. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[170] J. Wauters,et al. Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.
[171] M. Herselman,et al. Protein-energy malnutrition as a risk factor for increased morbidity in long-term hemodialysis patients. , 2000, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.
[172] R. Zubler. Antigens, T Dependent and Independent , 1998 .
[173] B. Seckler,et al. Tuberculin and anergy skin testing of patients receiving long-term hemodialysis. , 1998, Chest.
[174] A. Pasternack,et al. Intravenous calcitriol therapy restores reduced antigen-induced T-lymphocyte response in 1,25-(OH)2D3-deficient hemodialysis patients. , 1996, Nephron.
[175] G. Stein,et al. Influence of recombinant human erythropoietin therapy on in vivo chemotaxis and in vitro phagocytosis of polymorphonuclear cells of hemodialysis patients. , 1996, Blood purification.
[176] M. Fujishima,et al. Cellular immunity in hemodialysis patients: a quantitative analysis of immune cell subsets by flow cytometry. , 1995, American journal of nephrology.
[177] D. Satcher. Screening for tuberculosis and tuberculosis infection in high-risk populations. Recommendations of the Advisory Council for the Elimination of Tuberculosis. , 1995, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[178] E. Vonesh,et al. Nutritional status in the elderly patient with uraemia. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[179] G. Lonnemann,et al. The effect of ultrafiltered dialysate on the cellular content of interleukin-1 receptor antagonist in patients on chronic hemodialysis. , 1994, Nephron.
[180] J. Maciejewski,et al. Non-responsiveness to hepatitis B vaccination in haemodialysis patients: association with impaired TCR/CD3 antigen receptor expression regulating co-stimulatory processes in antigen presentation and recognition. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[181] J. Riancho,et al. Vitamin D therapy modulates cytokine secretion in patients with renal failure. , 1993, Nephron.
[182] C. Baldamus,et al. Signalling via the TCR/CD3 antigen receptor complex in uremia is limited by the receptors number. , 1993, Nephron.
[183] W. Hörl,et al. Uremia and infection: mechanisms of impaired cellular host defense. , 1993, Nephron.
[184] M. Oppermann,et al. Gene expression of interleukin-1 beta during hemodialysis. , 1993, Kidney international.
[185] M. Egidi,et al. The effect of transfusions on renal allograft survival in the cyclosporine era: a single center report. , 1993, Clinical transplantation.
[186] H. DeLuca,et al. 1 alpha, 25-Dihydroxyvitamin D3 and 19-nor-1 alpha, 25-dihydroxyvitamin D2 suppress immunoglobulin production and thymic lymphocyte proliferation in vivo. , 1993, Biochimica et biophysica acta.
[187] M. Singh,et al. The effects of recombinant human erythropoietin on the cell mediated immune response of renal failure patients. , 1992, Journal of medicine.
[188] B. Kristal,et al. Regulation of interleukin-2 and interferon-gamma gene expression in renal failure. , 1991, Kidney international.
[189] J. Riancho,et al. Effect of physiological concentrations of calcitriol on lymphocyte proliferation in normal subjects and in patients with renal failure. , 1990, Nephron.
[190] J. Berden,et al. Systemic lupus erythematosus: analysis of disease activity in 55 patients with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Dutch Working Party on SLE. , 1990, The American journal of medicine.
[191] M. Goldman,et al. Bacterial infections in chronic hemodialysis patients: epidemiologic and pathophysiologic aspects. , 1990, Advances in nephrology from the Necker Hospital.
[192] P. Fondu,et al. Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients. , 1990, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[193] S. Chouaib,et al. Prostaglandins E as modulators of the immune response. , 1988, Lymphokine research.
[194] S. Lewis,et al. Alterations in chemotactic factor-induced responses of neutrophils and monocytes from chronic dialysis patients. , 1988, Clinical nephrology.
[195] T. Shoji,et al. In vivo effect of 1 alpha-hydroxyvitamin D3 on interleukin-2 production in hemodialysis patients. , 1988, Nephron.
[196] K. zum Büschenfelde,et al. Active hepatitis B vaccination of dialysis patients and medical staff. , 1984, Kidney international.
[197] L. Moore,et al. Malnutrition as the main factor in morbidity and mortality of hemodialysis patients. , 1983, Kidney international. Supplement.
[198] F. Valderrábano,et al. Transfusion-induced anergy: skin test as an index for pretransplant transfusions. , 1983, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.
[199] R. Coppo,et al. Effects of blood transfusion on cellular immunity. , 1981, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.
[200] J. Jervell,et al. Influence of blood transfusions on kidney transplant and uremic patient survival. , 1977, Scandinavian journal of urology and nephrology. Supplementum.